Moderna completes FDA submissions for COVID-19 shot in those under 18
Maddie Meyer/Getty Images News


Moderna (NASDAQ:MRNA) confirmed the completion of its regulatory submissions to the U.S. Food and Drug Administration (FDA) seeking emergency use authorization (EUA) for its COVID-19 vaccine for those under 18 years.
The companyâs two-dose mRNA vaccine branded as Spikevax is currently authorized in the U.S. as a primary series and as a booster shot for the prevention of COVID-19 in adults at the 100 Î¼g dose.

With the recent earnings release, Moderna (MRNA) said it initiated a EUA submission for use of a 50 Î¼g primary series in children 6-11 years of age.
For adolescents aged 12 to 17 years, the company recently expanded its previous EUA submission with additional data at the request of the FDA. 
In late April, Moderna (MRNA) announced the submission of a EUA seeking the U.S. regulatory nod for the mRNA-1273 vaccine in children aged 6 months to 6 years of age at the 25 Î¼g dose.
Read: Today, the Centers for Disease Control and Prevention (CDC) said that a group of its experts would meet next week to discuss COVID-19 vaccines. The subject of the meeting was not disclosed.